Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Zaiss

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
European Journal of Haematology|August 10, 2018
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study)Jürgen Wehmeyer, Matthias Zaiss, Christoph Losem, et al.
Leukemia|April 25, 2025
Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM)Florian H Heidel, Valerio De Stefano, Matthias Zaiss, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line SettingThomas Decker, Matthias Zaiss, Dunja Klein, et al.
BMC Cancer|June 13, 2023
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practiceUwe M Martens, Jan Schröder, Fee Bengsch, et al.
International Journal of Cancer|December 21, 2024
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registryMarc Thill, Mark-Oliver Zahn, Anja Welt, et al.
Oncology Research and Treatment|November 17, 2024
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B TrialManfred Welslau, Karin Potthoff, Matthias Zaiss, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyNadia Harbeck, Denise Wrobel, Matthias Zaiss, et al.
Trials|May 17, 2023
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrantTom Degenhardt, Peter A Fasching, Diana Lüftner, et al.
Oncology Research and Treatment|May 14, 2015
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim AnalysisChristian M Kurbacher, Thomas Fietz, Ingo J Diel, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
European Journal of Haematology|August 10, 2018
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study)Jürgen Wehmeyer, Matthias Zaiss, Christoph Losem, et al.
Leukemia|April 25, 2025
Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM)Florian H Heidel, Valerio De Stefano, Matthias Zaiss, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line SettingThomas Decker, Matthias Zaiss, Dunja Klein, et al.
BMC Cancer|June 13, 2023
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practiceUwe M Martens, Jan Schröder, Fee Bengsch, et al.
International Journal of Cancer|December 21, 2024
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registryMarc Thill, Mark-Oliver Zahn, Anja Welt, et al.
Oncology Research and Treatment|November 17, 2024
Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B TrialManfred Welslau, Karin Potthoff, Matthias Zaiss, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyNadia Harbeck, Denise Wrobel, Matthias Zaiss, et al.
Trials|May 17, 2023
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrantTom Degenhardt, Peter A Fasching, Diana Lüftner, et al.
Oncology Research and Treatment|May 14, 2015
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim AnalysisChristian M Kurbacher, Thomas Fietz, Ingo J Diel, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Pageof 3